Compare Citius Pharmaceuticals Inc (CTXR) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VanEck Video Gaming and eSports ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while VanEck Video Gaming and eSports ETF trades at $100.11 (market cap $248.06M). The key difference: VanEck Video Gaming and eSports ETF is far larger — about 18.2× Citius Pharmaceuticals Inc's market cap, and VanEck Video Gaming and eSports ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and VanEck Video Gaming and eSports ETF for 66 Days on average.
| CTXR | ESPO | |
|---|---|---|
Market Cap | $13.62M | $248.06M |
Volume | 132,438 | 13,622 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $118.68 |
52-Week Low | $0.48 | $85.25 |
Typical Hold Time | 17 Days | 66 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
ESPO stock shows strong technical momentum, gaining 2.87% to $100.11 with a bullish moving average signal. The stock trades near resistance levels at $98-$99 while maintaining support at $97. Technical indicators show mixed signals with neutral RSI readings but positive ADX momentum. Fundamental data remains limited pending updated financial disclosures.
The technical setup suggests near-term upside potential if resistance levels are breached, though limited fundamental visibility warrants caution. Key risks include lack of recent financial data and market volatility. Investors require updated earnings reports and analyst coverage for proper valuation assessment before establishing positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
